News headlines about China Biologic Products (NASDAQ:CBPO) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. China Biologic Products earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 44.7620278163414 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of China Biologic Products (NASDAQ:CBPO) traded up $2.25 during trading on Wednesday, hitting $83.67. The company’s stock had a trading volume of 217,623 shares, compared to its average volume of 233,350. China Biologic Products has a fifty-two week low of $71.85 and a fifty-two week high of $120.46. The firm has a market capitalization of $2,700.00, a PE ratio of 35.16, a P/E/G ratio of 1.17 and a beta of 1.62.
China Biologic Products (NASDAQ:CBPO) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.89 by $0.01. China Biologic Products had a return on equity of 21.30% and a net margin of 18.34%. The firm had revenue of $90.10 million during the quarter, compared to analysts’ expectations of $85.15 million. During the same quarter last year, the firm earned $0.95 earnings per share. The business’s revenue for the quarter was up 16.1% on a year-over-year basis. research analysts anticipate that China Biologic Products will post 5.09 earnings per share for the current fiscal year.
About China Biologic Products
China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.